Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

Source: 
Biopharma Dive
snippet: 

Mark this year's American Society of Hematology meeting as one of the last times the biopharma community sees Celgene as an independent company.

The storied biotech is going out with a bang, however, with plans to release pivotal trial results for its leading cancer cell therapy lisocabtagene maraleucel, or liso-cel. Securing FDA approval of the drug by the end of 2020 is an essential step to its investors receiving $6 billion more from buyer Bristol-Myers Squibb.